Browse by author
Lookup NU author(s): Professor Quentin AnsteeORCiD
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND).
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.GOALS AND BACKGROUND: A panel of 9 experts in nonalcoholic steatohepatitis gathered to assess multiple components of the diagnostic process. MATERIALS AND METHODS: The Clinical Assertion Statements covered screening of patients with type 2 diabetes for high-risk nonalcoholic fatty liver disease, which-if any-noninvasive tests could determine whether to delay or defer biopsy, whether primary care providers and endocrinologists should routinely calculate Fibrosis-4 (FIB-4) scores in patients with nonalcoholic fatty liver disease or those at risk for it, optimal noninvasive tests to stage fibrosis, the need to consider fibrosis in patients with normal transaminase levels, periodic monitoring for progressive fibrosis, whether patients should undergo biopsy before pharmacotherapy, and the clinical utility of genetic testing. RESULTS AND CONCLUSIONS: Evidence was presented to support or refute each Clinical Assertion Statement; the panel voted on the nature of the evidence, level of support, and level of agreement with each Statement. Panel level of agreement and rationale of each Clinical Assertion Statement are reported here.
Author(s): Jacobson IM, Wong VW-S, Castera L, Anstee QM, Noureddin M, Cusi K, Harrison SA, Bugianesi E, Younossi ZM
Publication type: Article
Publication status: Published
Journal: Journal of Clinical Gastroenterology
Year: 2023
Volume: 57
Issue: 3
Pages: 253-264
Print publication date: 01/03/2023
Acceptance date: 02/04/2022
Date deposited: 28/02/2023
ISSN (print): 0192-0790
ISSN (electronic): 1539-2031
Publisher: Lippincott Williams & Wilkins
URL: https://doi.org/10.1097/MCG.0000000000001780
DOI: 10.1097/MCG.0000000000001780
PubMed id: 36251413
Altmetrics provided by Altmetric
